Atopic Dermatitis patient

We are researching and developing new therapeutic candidates that may have a significant impact on people affected by immune system disorders

  1. Home
  2. Areas of Focus
  3. Immunology

Expanding our research focus, we are targeting unmet needs in immune diseases including atopic dermatitis, rheumatoid arthritis, asthma, nasal polyposis, and eosinophilic esophagitis.

Immunology is an area of growth for us, and an area in which we hope to make a significant difference in patients’ lives. In collaboration with Regeneron, we currently have two therapies on the market and are researching and developing several new therapeutic areas.

The first therapy, approved in the U.S. and Europe, is indicated for adults with inadequately controlled moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease and the most common form of eczema. A second therapy, approved in the U.S., Canada, and Europe, is indicated for adults with moderate to severe rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints.

We are also studying other allergic and respiratory diseases, including asthma, nasal polyposis, and eosinophilic esophagitis.

Inspired by patients around the world

Rheumatoid arthritis patient
Atopic dermatitis patient
Atopic dermatitis patient

Above from left to right: Catherine, rheumatoid arthritis, USA; Hilde, atopic dermatitis, Norway; Vergard, atopic dermatitis, Norway

Understand AD logo

Atopic dermatitis: From education to empowerment

Understand AD is a national awareness campaign focused on educating people about moderate-to-severe atopic dermatitis (AD), a chronic form of eczema that can be serious. By educating Americans about the physical and quality of life impact of atopic dermatitis, Understand AD will give a voice to and empower the people living with the disease.
SAUS.GZ.17.11.9007
Last update: 1/2018